Table 1.

Patient characteristics

Demographics	All participants with CRS
No. of participants	53
Sex
Male	34 (64)
Female	19 (36)
Median age, years, (range)	15 (4–30)
Diagnosis
ALL	52 (98.1)
DLBCL	1 (1.9)
Prior HSCT	36 (68)
Prior CAR therapy	33 (62)
Evaluable for coagulopathy*	48

Data presented as No. (%) unless otherwise indicated.

*Five patients were excluded for evaluation of coagulopathy due to lack of laboratory measurements collected in these patients for the coagulopathy parameters of fibrinogen, ferritin, D-dimer and partial thromboplastin time. These five were among the earliest to be treated in the trial and importantly had no manifestations of bleeding.

ALL, acute lymphoblastic leukemia; CAR, chimeric antigen receptor; CRS, cytokine release syndrome; DLBCL, diffuse large B-cell lymphoma; HSCT, hematopoietic stem cell transplantation; INR, international normalized ratio; LD, lymphodepletion; LDH, lactate dehydrogenase; PCA, principle component analysis; VGEF, vascular endothelial growth factor.